EDSA - Edesa says mid-stage trial for anti-allergic cream reached full enrollment

• Edesa Biotech, Inc. ( NASDAQ: EDSA ), a Canadian company focused on inflammatory and immune-related diseases, added ~7% in the pre-market trading Wednesday after the biotech announced it reached the full enrollment of its Phase 2b clinical study for anti-allergic treatment EB01.
• The double-blind, confirmatory study is designed to evaluate EB01, a topical drug, as a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD) involving nearly 170 evaluable subjects.
• The company plans to complete the primary treatment period for trial subjects within the next 30 days, with a topline data readout expected by the end of 2022.
• However, EDSA is moving forward with its plans to market EB01 even as study results are pending and remain subject to regulatory review.
• The company seeks licensing or partnering arrangements to further develop and commercialize EB01 in the key markets it targets in North America, Par Nijhawan, EDSA’s Chief Executive, remarked.

• A developer of COVID-19 therapy called EB05, EDSA has won the Canadian approval to study the monoclonal antibody as a rescue therapy for critically ill patients.

For further details see: